Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.81 |
| ▸ | BACE1 | P56817 | 5/20 | 0.81 |
| ▸ | BCL2 | P10415 | 4/20 | 0.81 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.81 |
| ▸ | SNCA | P37840 | 4/20 | 0.81 |
| ▸ | PGD | P52209 | 4/20 | 0.81 |
| ▸ | PKM | P14618 | 3/20 | 0.81 |
| ▸ | MET | P08581 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | RECQL | P46063 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.81 |
| ▸ | APP | P05067 | 2/20 | 0.81 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.81 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.81 |
| ▸ | CNR1 | P21554 | 2/20 | 0.81 |
| ▸ | CNR2 | P34972 | 2/20 | 0.81 |
| ▸ | RAD52 | P43351 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17430773 | 1.00 | DYRK1A (0.81) | DYRK1ABACE1BCL2PSMB5SNCA | |
| SCHEMBL17107164 | 1.00 | DYRK1A (0.81) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epigallocatechin 3,5-Digallate SCHEMBL27785415 | 0.93 | DYRK1A (0.80) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epigallocatechin 3,5-Digallate SCHEMBL30262609 | 0.93 | DYRK1A (0.80) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epigallocatechin 3,5-Digallate SCHEMBL13287219 | 0.93 | DYRK1A (0.80) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL13014548 | 0.90 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL4545330 | 0.90 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL8426343 | 0.90 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL39047 | 0.90 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL39046 | 0.90 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112387103-A | Catechin formaldehyde scavenger and preparation method thereof | 中科恩吉瑞特(烟台)科技发展有限公司 | 2021-02-23 | — | — | CN | claimed |
| CN-112387103-A | Catechin formaldehyde scavenger and preparation method thereof | 中科恩吉瑞特(烟台)科技发展有限公司 | 2021-02-23 | — | — | CN | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20150272939-A1 | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase | YALE UNIVERSITY (US) | 2015-10-01 | — | — | US | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-20110236550-A1 | STABILIZATION OF PHENOLIC ANTIOXIDANTS IN FAT-CONTAINING FOODS | PERLMAN CONSULTING, LLC | 2011-09-29 | — | — | US | disclosed |
| EP-1560576-A4 | SYNTHESIS OF OLIGOMERIC EPICATECHIN AND CATECHIN-DERIVED PROCYANIDINS | MARS INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20050277600-A1 | Compositions and methods of use of dimer digallates | MARS, INCROPORATED (US) | 2005-12-15 | — | — | US | disclosed |
| EP-1560576-A2 | SYNTHESIS OF OLIGOMERIC EPICATECHIN AND CATECHIN-DERIVED PROCYANIDINS | MARS, INCORPORATED (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-1169304-B1 | 8-8, 6-6 AND 6-8 CATECHIN AND EPICATECHIN DIMERS AND METHODS FOR THEIR PREPARATION | MARS INC (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2004030440-A2 | SYNTHESIS OF OLIGOMERIC EPICATECHIN AND CATECHIN-DERIVED PROCYANIDINS | MARS, INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
| EP-1169304-A4 | 8-8, 6-6 AND 6-8 CATECHIN AND EPICATECHIN DIMERS AND METHODS FOR THEIR PREPARATION | MARS INC (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1169304-A1 | 8-8, 6-6 AND 6-8 CATECHIN AND EPICATECHIN DIMERS AND METHODS FOR THEIR PREPARATION | Mars Incorporated (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6156912-A | 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation | MARS, INCORPORATED (US) | 2000-12-05 | — | — | US | disclosed |
| WO-2000061547-A1 | 8-8, 6-6 AND 6-8 CATECHIN AND EPICATECHIN DIMERS AND METHODS FOR THEIR PREPARATION | MARS, INCORPORATED (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277600-A1 | Compositions and methods of use of dimer digallates | FABP3, FGB, F2 | DYRK1A 1725/4885BACE1 2764/4885BCL2 693/4885 |
| US-20150272939-A1 | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase | KDM1B, KDM1A, JMJD1C | DYRK1A 2632/4885BACE1 3912/4885BCL2 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.